Brainsway (BWAY) Stock Price, News & Analysis

Company Overview

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

Key Stats

• Today's Range: $12.88 to $13.25
• 50-Day Range: $8.61 to $13.22
• 52-Week Range: $5.67 to $13.35
• Volume: 33,240 shs
• Average Volume: 67,672 shs
• Market Capitalization: $248.54 million
• P/E Ratio: 65.75
• Dividend Yield: N/A
• Price Target: $14.25
• Consensus Rating: Buy

Brainsway Stock Analysis - MarketRank™

Brainsway scored higher than 22% of companies evaluated by MarketBeat, and ranked 835th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

Brainsway has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Brainsway has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 100.00%

Earnings Growth

Earnings for Brainsway are expected to grow by 100.00% in the coming year, from $0.08 to $0.16 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Brainsway is 65.75, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Brainsway is 65.75, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.64.

Price to Book Value per Share Ratio

Brainsway has a P/B Ratio of 3.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.82% of the float of Brainsway has been sold short.

Short Interest Ratio / Days to Cover

Brainsway has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Brainsway has recently increased by 21.41%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Brainsway does not currently pay a dividend.

Dividend Growth

Brainsway does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.82% of the float of Brainsway has been sold short.

Short Interest Ratio / Days to Cover

Brainsway has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Brainsway has recently increased by 21.41%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Brainsway to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Brainsway insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.00% of the stock of Brainsway is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 30.11% of the stock of Brainsway is held by institutions.

BWAY Stock Analysis - Frequently Asked Questions

How have BWAY shares performed this year?

Brainsway's stock was trading at $9.43 at the beginning of the year. Since then, BWAY stock has increased by 39.4% and is now trading at $13.15.

How were Brainsway's earnings last quarter?

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) issued its quarterly earnings results on Tuesday, May, 13th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.02. The company had revenue of $11.54 million for the quarter, compared to analysts' expectations of $11.45 million. Brainsway had a trailing twelve-month return on equity of 7.35% and a net margin of 9.01%.
Read the conference call transcript.

When did Brainsway IPO?

Brainsway (BWAY) raised $30 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 2,500,000 shares at $11.94 per share. Cantor served as the underwriter for the IPO.

How do I buy shares of Brainsway?

Shares of BWAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Brainsway own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Brainsway investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Novo Nordisk A/S (NVO) and AppLovin (APP).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BWAY
• CIK: 1505065
• Web: www.brainsway.com
• Phone: (722) 582-4030
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.25
• High Stock Price Target: $16.00
• Low Stock Price Target: $12.50
• Potential Upside/Downside: +8.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.20
• Trailing P/E Ratio: 65.75
• Forward P/E Ratio: 164.38
• P/E Growth: N/A
• Net Income: $2.92 million
• Net Margins: 9.01%
• Pretax Margin: 10.22%
• Return on Equity: 7.35%
• Return on Assets: 4.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.03
• Quick Ratio: 4.75

Sales & Book Value

• Annual Sales: $41.02 million
• Price / Sales: 6.06
• Cash Flow: $0.25 per share
• Price / Cash Flow: 53.10
• Book Value: $3.31 per share
• Price / Book: 3.97

Miscellaneous

• Outstanding Shares: 18,900,000
• Free Float: 15,305,000
• Market Cap: $248.54 million
• Optionable: Not Optionable
• Beta: 1.40